Evolution of Chronic Inflammatory Skin Diseases (EPICA)

monocentric retrospective-prospective observational study evaluating the clinical evolution of common chronic inflammatory skin diseases, including atopic dermatitis, psoriasis, prurigo nodularis, chronic hand eczema, and hidradenitis suppurativa. The study will collect demographic, clinical, therapeutic, and validated clinimetric data from patients aged ≥12 years. Its primary aim is to describe changes in disease severity over time. Secondary objectives include identifying demographic, clinical, and treatment-related predictors of moderate-to-severe disease and unfavorable outcomes. Data will cover a 7-year retrospective period and a 10-year prospective follow-up.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

5000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Rome, Italy, 00168
        • Recruiting
        • Fondazione Policlinico Agostino Gemelli IRCCS
        • Contact:
          • Ketty Peris, Prof

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients affected with inflammatory skin conditions including atopic dermatitis, prurigo nodularis, Hidradenitis suppurativa, psoriasis

Description

Inclusion Criteria:

  • Age ≥12 years.
  • Patients with a confirmed clinical diagnosis of atopic dermatitis (AD), prurigo nodularis (PN), psoriasis (PSO), chronic hand eczema (CHE), or hidradenitis suppurativa (HS) attending the dermatology outpatient clinics of Fondazione Policlinico Universitario A. Gemelli IRCCS.
  • Availability of clinical data at baseline and at subsequent follow-up visits performed according to routine clinical practice.

Exclusion Criteria:

  • Age <12 years; absence of the minimum required data (treatment start date and at least one follow-up visit with a clinical score).
  • Refusal or inability to understand and sign the informed consent form.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: OTHER

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change Over Time in Eczema Area and Severity Index (EASI)
Time Frame: Baseline and every 16 ± 4 weeks, up to 120 months

Change over time in Eczema Area and Severity Index (EASI) in participants with atopic dermatitis. EASI ranges from 0 to 72, with higher scores indicating greater disease severity.

Baseline and every 16 ± 4 weeks, up to 120 months
Change Over Time in SCORing Atopic Dermatitis (SCORAD)
Time Frame: Baseline and every 16 ± 4 weeks, up to 120 months

Change over time in SCORing Atopic Dermatitis (SCORAD) in participants with atopic dermatitis. SCORAD ranges from 0 to 103, with higher scores indicating greater disease severity.

Baseline and every 16 ± 4 weeks, up to 120 months
Change Over Time in Patient-Oriented Eczema Measure (POEM)
Time Frame: Baseline and every 16 ± 4 weeks, up to 120 months

Change over time in Patient-Oriented Eczema Measure (POEM) in participants with atopic dermatitis. POEM ranges from 0 to 28, with higher scores indicating greater patient-reported disease severity.

Baseline and every 16 ± 4 weeks, up to 120 months
Change Over Time in Psoriasis Area and Severity Index (PASI)
Time Frame: Baseline and every 16 ± 4 weeks, up to 120 months

Change over time in Psoriasis Area and Severity Index (PASI) in participants with psoriasis. PASI ranges from 0 to 72, with higher scores indicating greater disease severity.

Baseline and every 16 ± 4 weeks, up to 120 months
Change Over Time in Hand Eczema Severity Index (HECSI)
Time Frame: Baseline and every 16 ± 4 weeks, up to 120 months

Change over time in Hand Eczema Severity Index (HECSI) in participants with chronic hand eczema. HECSI ranges from 0 to 360, with higher scores indicating greater disease severity.

Baseline and every 16 ± 4 weeks, up to 120 months
Change Over Time in Investigator's Global Assessment for Prurigo Nodularis
Time Frame: Baseline and every 16 ± 4 weeks, up to 120 months

Change in Investigator Global Assessment (IGA) in patients with prurigo nodularis

Baseline and every 16 ± 4 weeks, up to 120 months
Change Over Time in Itch Numerical Rating Scale (NRS)
Time Frame: baseline and every 16 ± 4 weeks, up to 120 months

Change over time in itch intensity assessed using the Numerical Rating Scale (NRS). Scores range from 0 to 10, where 0 indicates no itch and 10 indicates the worst imaginable itch. Higher scores indicate worse itch.

baseline and every 16 ± 4 weeks, up to 120 months
Change Over Time in Sleep Numerical Rating Scale (NRS)
Time Frame: baseline and every 16 ± 4 weeks, up to 120 months

Change over time in sleep disturbance assessed using the Numerical Rating Scale (NRS). Scores range from 0 to 10, with higher scores indicating greater sleep disturbance.

baseline and every 16 ± 4 weeks, up to 120 months
Change Over Time in Dermatology Life Quality Index (DLQI)
Time Frame: baseline and every 16 ± 4 weeks, up to 120 months

Change over time in Dermatology Life Quality Index (DLQI). Scores range from 0 to 30, with higher scores indicating greater impairment in dermatology-related quality of life.

baseline and every 16 ± 4 weeks, up to 120 months
Change Over Time in Hurley Stage
Time Frame: baseline and every 16 ± 4 weeks, up to 120 months

Change over time in hidradenitis suppurativa severity according to Hurley staging. Hurley stage ranges from Stage I to Stage III, with higher stages indicating more severe disease.

baseline and every 16 ± 4 weeks, up to 120 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Ketty Peris, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2026

Primary Completion (Estimated)

July 1, 2030

Study Completion (Estimated)

July 1, 2036

Study Registration Dates

First Submitted

July 13, 2026

First Submitted That Met QC Criteria

July 13, 2026

First Posted (Actual)

July 16, 2026

Study Record Updates

Last Update Posted (Actual)

September 25, 2026

Last Update Submitted That Met QC Criteria

September 23, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 27085

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.